Why Is G1 Therapeutics (GTHX) Stock Up 66% Today? G1 Therapeutics stock is up on Wednesday following news that Pharmacosmos Group is acquiring GTHX for $7.15 per share.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025 While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood.
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal.
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees.
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts Ginkgo Bioworks layoffs are a hot topic as the company prepares to cut 158 jobs this week with more headcount reductions coming next week.
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and cardiovascular events.
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC.
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today? G1 Therapeutics stock is down on Monday as GTHX investors react to the company's Phase 3 clinical trial of trilaciclib failing.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning!
What's Going On With G1 Therapeutics Stock? According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right which could value the company at between $12 and $14 per share.
GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024 GTHX stock results show that G1 Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
